-
Sen. Chuck Grassley (R-Iowa) and Sen. Herb Kohl (D-WI) have introduced legislation that would require not only pharmaceutical companies, but also makers of medical devices and biologics, to publicly report any money over $100 that they give to physicians within a year.
-
President Obama may have signed the $787 billion stimulus package with the expectation that it will create jobs and jumpstart the economy, but businesses including those in the business of health care are still feeling financial pain.
-
Planned Parenthood Federation of America (PPFA) and Planned Parenthood of Connecticut were among those filing lawsuits asking the U.S. District Court for the District of Connecticut to invalidate the administrative regulation finalized in December by the U.S. Department of Health aÿ
-
[Editor's note: Medical Ethics Advisor will update this story in the April issue. Prior to press time, NHPCO secured a one-year moratorium on cuts in the Medicare Hospice Benefit via President Barack Obama's signing of The American Recovery and Reinvestment Act of 2009.]
-
If you ask Laura Ann Wagner, president and CEO of In-House Hopice, based in Southfield, MI, the explanation why costs are increasing for the Medicare hospice benefit the answer is a simple one: Baby boomers are aging, and more of them are taking advantage of that benefit.
-
Q & A with Felicia Cohn, PhD, director of medical ethics, University of California, Irvine, School of Medicine.
-
SouthernCare Inc. and its shareholders agreed to pay the United States a total of $24.7 million to settle allegations that the company submitted false claims to the government for patients treated at its hospice facilities, the U.S. Justice Department reported in mid-January.
-
Post-extubation laryngeal edema, although infrequent, can necessitate reintubation and lead to other complications.
-
Despite concerns that recombinant human Activated Protein C (rhAPC) is associated with an increased risk of bleeding, the FDA failed to list several of the bleeding-related exclusion criteria used in the PROWESS trial as contraindications to use of this agent.
-
Pulmonary hypertension (ph) is common among patients in the intensive care unit (ICU). In fact, many ICU clinicians simply view PH the same way they view leukocytosis as an expected finding caused by the "bigger problems" of sepsis, respiratory failure, congestive heart failure, volume overload, and myocardial infarction.
